Insulin sensitizers have been used to treat Type 2 diabetes. However, their
non-negligible side effects have led to cardiovascular concerns and the withdrawal of a
member, rosiglitazone.
OBJECTIVE:
We combined conjugated linoleic acid (CLA) with rosiglitazone to test for amelioration
of side effects posed by rosiglitazone in vivo.
METHODS:
We utilized ApoE null mice fed with Western diet (WD) to test our hypothesis. Mice were
fed WD, with or without CLA administration, for 12 weeks. CLA utilized in our study
consisted of a 1:1 ratio of 95% pure c9,t11, and
t10,c12 isomers at a concentration of 0.1% w/v in fat-free milk.
Starting from Week 12, select mice received rosiglitazone.
RESULTS:
It was found that mice receiving CLA from Week 0 and rosiglitazone from Week 12 had the
lowest body weight and exacerbated hepatomegaly. Although these mice had attenuated
insulin resistance compared to mice receiving only Western diet, they display a marked
increase in total plasma cholesterol and low-density lipoprotein (LDL) cholesterol. Mice
receiving early CLA administration developed hyperleptinemia, which was not restored by
rosiglitazone.
CONCLUSION:
Taken together, against the background of ApoE null genotype and WD feeding,
simultaneous administration of 1:1 CLA and rosiglitazone led to dyslipidemic
lipoatrophy.
MooradianAD.
Dyslipidemia in type 2 diabetes mellitus. Nat Rev
Endocrinol.
2009;5:150–9.
3.
BösenbergLH, van
ZylDG. The mechanism
of action of oral antidiabetic drugs: A review of recent literature.
J Endocrinol Metab Diabetes South Africa.
2008;13:80–8.
4.
ChaudhuryA, DuvoorC, Reddy
DendiVS, et al.
Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes
Mellitus Management. Front Endocrinol (Lausanne).
2017;8:e1.
5.
ChaoL, Marcus-SamuelsB,
MasonMM, et
al. Adipose tissue is required for the antidiabetic, but not for the
hypolipidemic, effect of thiazolidinediones. J Clin
Invest.
2000;106:1221–8.
6.
SavageDB, PetersenKF, ShulmanGI.
Mechanisms of Insulin Resistance in Humans and Possible Links With
Inflammation. Hypertension.
2005;45:828–33.
7.
KellyIE, HanTS,
WalshK, et al.
Effects of a thiazolidinedione compound on body fat and fat distribution
of patients with type 2 diabetes. Diabetes Care.
1999;22:288LP–293.
8.
NestoRW, BellD,
BonowRO, et
al. Thiazolidinedione Use, Fluid Retention, and Congestive Heart
Failure. Circulation.
2003;108:2941–8.
9.
NissenSE, WolskiK.
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death
from Cardiovascular Causes. N Engl J Med.
2007;356:2457–71.
10.
GoldbergRB, KendallDM, DeegMA,
et al. A Comparison of Lipid and Glycemic Effects of
Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and
Dyslipidemia. Diabetes Care.
2005;28:1547–54.
11.
ShimWS, DoMY,
KimSK, et al.
The long-term effects of rosiglitazone on serum lipid concentrations and
body weight. Clin Endocrinol (Oxf).
2006;65:453–9.
12.
WilsonKD, LiZ,
WagnerR, et
al. Transcriptome Alteration in the Diabetic Heart by Rosiglitazone:
Implications for Cardiovascular Mortality. PLoS One.
2008;3:e2609.
13.
VerschurenL, WielingaPY, KelderT, et al.
A systems biology approach to understand the pathophysiological
mechanisms of cardiac pathological hypertrophy associated with
rosiglitazone. BMC Med Genomics.
2014;7:35.
14.
BeluryMA.
Inhibition of Carcinogenesis by Conjugated Linoleic Acid: Potential
Mechanisms of Action. J Nutr.
2002;132:2995–8.
15.
MillerJR, SiripurkpongP, HawesJ,
et al. The trans-10, cis-12 isomer of conjugated linoleic
acid decreases adiponectin assembly by PPARγ-dependent and PPARγ-independent
mechanisms. J Lipid Res.
2008;49:550–62.
16.
ClémentL, PoirierH, NiotI,
et al. Dietary trans-10,cis-12conjugated linoleic acid
induces hyperinsulinemia and fatty liver inthe mouse. J Lipid
Res.
2002;43:1400–9.
17.
ChaiBK, Al-ShaggaM, PanY,
et al. Cis-9, Trans-11 Conjugated Linoleic Acid Reduces
Phosphoenolpyruvate Carboxykinase Expression and Hepatic Glucose Production in HepG2
Cells. Lipids.
2019;54:369–79.
18.
ChaiBK, LauYS,
LoongBJ, et
al. Co-Administration of Conjugated Linoleic Acid and Rosiglitazone
Increases Atherogenic Co-Efficient and Alters Isoprenaline-Induced Vasodilatation in
Rats Fed High Fat Diet. Physiol Res.
2018;67:729–40.
19.
PetterssonUS,
WaldénTB, CarlssonP-O, et
al. Female Mice areProtected against High-Fat Diet Induced
Metabolic Syndrome andIncrease the Regulatory T Cell Population in Adipose
Tissue. PLoS One.
2012;7:e46057.
20.
ParraP, PalouA,
SerraF.
Moderate doses of conjugated linoleic acid reduce fat gain, maintain
insulin sensitivity without impairing inflammatory adipose tissue status in mice fed a
high-fat diet. Nutr Metab (Lond).
2010;7:5.
21.
ZhouM, XuH,
LiuW, et al.
Rosiglitazone modulates collagen deposition and metabolism in
atherosclerotic plaques of fat-fed ApoE-knockout mice. Exp Ther
Med.
2015;10:1265–70.
22.
MohankumarSK,
HankeD, SiemensL, et
al. Dietary supplementation of trans -11-vaccenic acid reduces
adipocyte size but neither aggravates nor attenuates obesity-mediated metabolic
abnormalities in fa / fa Zucker rats. Br J Nutr.
2013;109:1628–36.
23.
HřebíčekJ, JanoutV, MalinčíkováJ, et
al. Detection of Insulin Resistance by Simple Quantitative
InsulinSensitivity Check Index QUICKI for Epidemiological Assessment
andPrevention. J Clin Endocrinol Metab.
2002;87:144–144.
24.
PerseghinG.
Incorporation of the Fasting Plasma FFA Concentration into QUICKI
Improves Its Association with Insulin Sensitivity in Nonobese
Individuals. J Clin Endocrinol Metab.
2001;86:4776–81.
25.
BeluryM, Moya-CamarenaS,
LuM.
Conjugated linoleic acid is an activator and ligand for peroxisome
proliferator-activated receptor-gamma (PPARγ). Nutr
Res.
2002;22:817–24.
26.
Moya-CamarenaSY,
Heuvel
VandenJP, BlanchardSG, et
al. Conjugated linoleic acid is a potent naturally occurring
ligand and activator of PPARα. J Lipid Res.
1999;40:1426–33.
27.
PlumpAS, SmithJD, HayekT,
et al. Severe hypercholesterolemia and atherosclerosis in
apolipoprotein E-deficient mice created by homologous recombination in ES
cells. Cell.
1992;71:343–53.
28.
NakashimaY, PlumpAS, RainesEW, et
al. ApoE-deficient mice develop lesions of all phases of
atherosclerosis throughout the arterial tree. Arterioscler
Thromb Vasc Biol.
1994;14:133–40.
29.
LiJ, WangQ,
ChaiW, et al.
Hyperglycemia in apolipoprotein E-deficient mouse strains with different
atherosclerosis susceptibility. Cardiovasc Diabetol.
2011;10:1–10.
30.
SchreyerSA, LystigTC, VickCM,
et al. Mice deficient in apolipoprotein E but not LDL
receptors are resistant to accelerated atherosclerosis associated with
obesity. Atherosclerosis.
2003;171:49–55.
31.
WangS, GoodspeedL, TurkKE,
et al. Rosiglitazone improves insulin resistance mediated by
10,12 conjugated linoleic acid in a male mouse model of metabolic
syndrome. Endocrinology.
2017;158:2848–59.
32.
HaladeGV, RahmanM, FernandesG.
Differential effects of conjugated linoleic acid isomers in
insulin-resistant female. J Nutr Biochem.
2010;21:332–7.
33.
ToomeyS, HarhenB, RocheHM, et al.
Profound resolution of early atherosclerosis with conjugated linoleic
acid. Atherosclerosis.
2006;187:40–9.
34.
Tsuboyama-KasaokaN,
TakahashiM, TanemuraK, et
al. Conjugated linoleic acid supplementation reduces adipose
tissue by apoptosis and develops lipodystrophy in mice.
Diabetes.
2000;49:1534–42.
35.
PoirierH, NiotI,
ClémentL, et
al. Development of conjugatedlinoleic acid (CLA)-mediated
lipoatrophic syndrome in the mouse. Biochimie.
2005;87:73–79.
36.
NotoA, ZahradkaP, YurkovaN, et
al. Conjugated linoleic acid reduces hepatic steatosis, improves
liver function, and favorably modifies lipid metabolism in obese insulin-resistant
rats. Lipids.
2006;41:179–88.
37.
ShimomuraI, HammerRE, IkemotoS, et
al. Leptin reverses insulin resistance and diabetes mellitus in
mice with congenital lipodystrophy. Nature.
1999;401:73–6.
38.
PetersenKF, OralEA,
DufourS, et
al. Leptin reverses insulin resistance and hepatic steatosis in
patients with severe lipodystrophy. J Clin Invest.
2002;109:1345–50.
39.
ColomboC, CutsonJJ, YamauchiT, et
al. Transplantation of adipose tissue lacking leptin is unable to
reverse the metabolic abnormalities associated with lipoatrophy.
Diabetes.
2002;51:2727–33.
40.
BabaY, KanekoH, TakemotoM, et
al. Case of lipoatrophic diabetes induced by juvenile
dermatomyositis. J Diabetes Investig.
2018;9:632–5.
41.
LiuL-F, PurushothamA, WendelAA, et
al. Combined effects of rosiglitazone and conjugated linoleic acid
on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed
mice. Am J Physiol Gastrointest Liver Physiol.
2007;292:G1671–82.
42.
SchierwagenR,
MaybüchenL, ZimmerS, et al.
Seven weeks of Western diet in apolipoprotein-E-deficient mice induce
metabolic syndrome and non-alcoholic steatohepatitis with liver
fibrosis. Sci Rep.
2015;5:1–14.
43.
García-RuizI,
Rodríguez-JuanC,
Díaz-SanjuánT, et
al. Effects of rosiglitazone on the liver histology
andmitochondrial function in ob/ob mice. Hepatology.
2007;46:414–23.
44.
HemmeryckxB, GaekensM, GallacherDJ, et
al. Effect of rosiglitazone on liver structure and function in
genetically diabetic Akita Mice. Basic Clin Pharmacol
Toxicol.
2013;113:353–60.
45.
KelleyDS, BartoliniGL, WarrenJM, et
al. Contrasting effects of t10,c12- and c9,t11-conjugated linoleic
acid isomers on the fatty acid profiles of mouse liver lipids.
Lipids.
2004;39:135–41.
46.
Antuna-PuenteB,
FarajM, KarelisAD, et
al. HOMA or QUICKI: Is it useful to test the reproducibility of
formulas?Diabetes Metab.
2008;34:294–6.
47.
Rabasa-LhoretR,
BastardJ-P, JanV,
et al. Modified Quantitative Insulin Sensitivity Check Index
Is Better Correlated to Hyperinsulinemic Glucose Clamp than Other Fasting-Based Index of
Insulin Sensitivity in Different Insulin-Resistant States. J
Clin Endocrinol Metab.
2003;88:4917–23.
48.
RahnT, RidderstråleM, TornqvistH, et
al. Essential role of phosphatidylinositol 3-kinase in
insulin-induced activation and phosphorylation of the cGMP-inhibited cAMP
phosphodiesterase in rat adipocytes studies using the selective inhibitor
wortmannin. FEBS Lett.
1994;350:314–8.
49.
MorimotoC, TsujitaT, OkudaH.
Antilipolytic actions of insulin on basal and hormone-induced lipolysis
in rat adipocytes. J Lipid Res.
1998;39:957–62.
50.
SearsB, PerryM.
The role of fatty acids in insulin resistance.
Lipids Health Dis.
2015;14:1–9.
51.
den
HartighL. Conjugated
Linoleic Acid Effects on Cancer, Obesity, and Atherosclerosis: A Review of Pre-Clinical
and Human Trials with Current Perspectives. Nutrients.
2019;11:370.
52.
BenjaminS, PrakasanP, SreedharanS, et
al. Pros and cons of CLA consumption: an insight from clinical
evidences. Nutr Metab (Lond).
2015;12:4.
53.
NooneEJ, RocheHM, NugentAP, et
al. The effect of dietary supplementation using isomeric blends of
conjugated linoleic acid on lipid metabolism in healthy human subjects.
Br J Nutr.
2002;88:243–51.
54.
TriconS, BurdgeGC, KewS,
et al. Opposing effects of cis-9,trans-11 and trans-10,cis-12 conjugated
linoleic acid on blood lipids in healthy humans. 2004.
55.
WandersAJ, BrouwerIA, SiebelinkE, et
al. Effect of a High Intake of Conjugated Linoleic Acid on
Lipoprotein Levels in Healthy Human Subjects. PLoS One.
2010;5:e9000.
56.
EyjolfsonV, SprietLL, DyckDJ.
Conjugated Linoleic Acid Improves Insulin Sensitivity in Young, Sedentary
Humans. Med Sci Sports Exerc.
2004;36:814–20.
57.
RisérusU, ArnerP,
BrismarK, et
al. Treatment with dietarytrans10cis12 conjugated linoleic acid
causes isomer-specific insulinresistance in obese men with the metabolic
syndrome. Diabetes Care.
2002;25:1516–21.
58.
RisérusU, VessbyB, ArnlövJ, et al.
Effects ofcis-9,trans-11 conjugated linoleic acid supplementation on
insulinsensitivity, lipid peroxidation, and proinflammatory markers inobese
men. Am J Clin Nutr.
2004;80:279–83.
59.
NorrisLE, ColleneAL, AspML,
et al. Comparison of dietary conjugated linoleic acid with
safflower oil on body composition in obese postmenopausal women with type 2 diabetes
mellitus. Am J Clin Nutr.
2009;90:468–76.
